Form 4: Kiniksa Pharmaceuticals Director Acquires New Options and RSUs, Converts Existing Units to Shares

Kiniksa Pharmaceuticals International, plc Director Kimberly J. Popovits reported the acquisition of new stock options and restricted share units, alongside the vesting and conversion of previously held restricted share units into Class A Ordinary Shares.

Summary

• Kimberly J. Popovits, a Director at Kiniksa Pharmaceuticals International, plc (KNSA), filed a Form 4 detailing recent transactions.
• On June 3, 2025, Ms. Popovits was granted 16,798 share options with an exercise price of $29.11, which will vest in twelve substantially equal monthly installments, with a final vesting on the earlier of the grant anniversary or the next annual meeting, and an expiration date of June 2, 2035.
• Also on June 3, 2025, Ms. Popovits was granted 2,799 Restricted Share Units (RSUs), which vest in their entirety on the earlier of the grant anniversary or the next annual meeting.
• On June 5, 2025, 3,173 Restricted Share Units vested and were converted into Class A Ordinary Shares.
• Following these transactions, Ms. Popovits directly beneficially owns 12,546 Class A Ordinary Shares and holds 16,798 share options and 2,799 Restricted Share Units.

Sentiment

Score: 7

Explanation: The filing reports the grant of new stock options and restricted share units to a director, along with the vesting and conversion of previously granted restricted share units into ordinary shares, indicating ongoing compensation and increased insider ownership, which is generally viewed positively as it aligns insider interests with shareholders.

Positives

• The grant of 16,798 new share options and 2,799 Restricted Share Units to a director indicates ongoing compensation and alignment of interests with shareholders.
• The vesting and conversion of 3,173 Restricted Share Units into Class A Ordinary Shares increases the director's direct ownership in the company.

Future Outlook

The granted share options are set to vest in twelve substantially equal monthly installments following the grant date of June 3, 2025, with final vesting on the earlier of the grant anniversary or the next annual meeting. The newly granted Restricted Share Units will vest in their entirety on the earlier of the grant anniversary or the next annual meeting.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to director compensation, and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the director's increased equity stake and ongoing compensation through equity grants as a positive sign of alignment between management and shareholder interests.

Next Steps

• Vesting of 16,798 share options over twelve monthly installments following June 3, 2025.
• Vesting of 2,799 Restricted Share Units on the earlier of June 3, 2026, or the date of the Issuer's annual meeting of shareholders in the following year.

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, Form 4, Insider Transaction, Stock Options, Restricted Share Units, Director Compensation, Equity Grant